Amgen Faces Growth Headwinds as Analysts Recommend Caution
PILLAR DIAGNOSTIC // WEEK 09
“Patent cliffs and intensifying pricing scrutiny will cap Amgen’s long‐run growth, but the tape and consensus earnings forecasts remain overly optimistic; a gradual repricing is likely as key patents expire and regulatory pressure mounts.”
Proposed action
Trim or hedge existing long exposure rather than add new positions; avoid chasing upside until these map‐driven headwinds are more fully reflected in price.
THE MECHANICS
Tape & flow
Selling 1,000 June 18, 2026 $340 put contracts for $9.00 each has generated $900,000 of premium, underscoring bullish options flow into AMGN.
THE MACHINE
Operational momentum
Revenue is forecast to reach $37.4 billion by 2028 (about 2.3% annual growth) backed by Q4 2025 sales of $9.9 billion and 2026 guidance of $37–38.4 billion, while robust adjusted EPS targets of $21.60–$23 and strong free cash flow underpin dividends, share buybacks, and continued investment capacity, further bolstered by a long-dated bond structure with change-of-control protections.
THE MAP
Structure & constraints
Amgen’s extensive pipeline across oncology, cardiovascular, inflammation, rare diseases and obesity faces significant external headwinds from intensifying drug pricing scrutiny, looming patent expiries and biosimilar competition, even as its rare disease unit delivers over $5 billion in annual revenue.
THE MOOD
Consensus & positioning
Analysts show mixed optimism, ranging from a Strong Buy consensus to a more cautious Moderate Buy stance alongside Barclays’ recent Equal Weight initiation. Investors are buoyed by a strong momentum narrative, even as the stock trades above its most followed fair value estimate.